Merck to expand cancer vaccine tech portfolio with Immune Design bid

Merck & Co. Inc. (NYSE:MRK) will acquire cancer vaccine company Immune Design Corp. (NASDAQ:IMDZ) to boost its cancer immunotherapy pipeline.

Merck will pay $5.85 per share in cash, or about $300 million. The price is a 312% premium

Read the full 373 word article

User Sign In